According to PerkinElmer 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 27.9193. At the end of 2021 the company had a P/E ratio of 25.1.
Year | P/E ratio | Change |
---|---|---|
2021 | 25.1 | 13.88% |
2020 | 22.0 | -53.52% |
2019 | 47.4 | 29.69% |
2018 | 36.6 | 33.01% |
2017 | 27.5 | 12.79% |
2016 | 24.4 | -14.38% |
2015 | 28.5 | -9.01% |
2014 | 31.3 | 11.34% |
2013 | 28.1 | -45.6% |
2012 | 51.6 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Thermo Fisher Scientific TMO | 31.3 | 12.27% | ๐บ๐ธ USA |
![]() Agilent Technologies A | 29.9 | 7.13% | ๐บ๐ธ USA |
![]() Becton Dickinson BDX | 45.5 | 63.05% | ๐บ๐ธ USA |
![]() Illumina ILMN | -8.25 | -129.56% | ๐บ๐ธ USA |
![]() Waters Corporation WAT | 26.2 | -6.03% | ๐บ๐ธ USA |
![]() Translate Bio
TBIO.defunct | N/A | N/A | ๐บ๐ธ USA |
![]() Bruker BRKR | 41.5 | 48.74% | ๐บ๐ธ USA |
![]() Bio-Rad Laboratories BIO | -3.87 | -113.86% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.